Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation-Reference-Cited by-同舟云学术

Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation

Published:2015-06 Issue:6 Volume:67 Page:1195-1196
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Ali Siraj M.,Miller Vincent A.,Ross Jeffrey S.,Pal Sumanta K.

Publisher

Elsevier BV

Subject

Urology

Reference5 articles.

1. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing;Frampton;Nat Biotechnol,2013

2. NCT01215136. First-line everolimus +/– paclitaxel for cisplatin-ineligible patients with advanced urothelial carcinoma. http://clinicaltrials.gov/ct2/show/NCT01215136.

3. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium;Sonpavde;Lancet Oncol,2010

4. Genome sequencing identifies a basis for everolimus sensitivity;Iyer;Science,2012

5. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib;Wagle;Cancer Discov,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal Cell Carcinoma of Variant Histology;Hematology/Oncology Clinics of North America;2023-10

2. Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas;Modern Pathology;2021-07-23

3. Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds;Clinical Genitourinary Cancer;2021-04

4. Genomic profiling in renal cell carcinoma;Nature Reviews Nephrology;2020-06-19

5. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss;Gynecologic Oncology;2020-05